AVDL
Avadel PharmaceuticalsAVDL
AVDL
About: Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.
Employees: 188
0
Funds holding %
of 7,430 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
39% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 49
17% more capital invested
Capital invested by funds: $611M [Q1] → $714M (+$103M) [Q2]
3.06% more ownership
Funds ownership: 80.33% [Q1] → 83.39% (+3.06%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 7 [Q1] → 7 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 26
0% less call options, than puts
Call options by funds: $2.07M | Put options by funds: $2.08M
2% less funds holding
Funds holding: 172 [Q1] → 168 (-4) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$20
35%
upside
Avg. target
$22
48%
upside
High target
$24
62%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
UBS Ashwani Verma | 35%upside $20 | Buy Maintained | 21 Aug 2025 |
HC Wainwright & Co. Raghuram Selvaraju | 62%upside $24 | Buy Maintained | 8 Aug 2025 |
Financial journalist opinion
Based on 6 articles about AVDL published over the past 30 days
Positive
Zacks Investment Research
2 weeks ago
Wall Street Analysts Predict a 37.25% Upside in Avadel (AVDL): Here's What You Should Know
The consensus price target hints at a 37.3% upside potential for Avadel (AVDL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
Seeking Alpha
2 weeks ago
Avadel Pharmaceuticals plc (AVDL) Q2 2025 Earnings Call Transcript
Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Gregory J. Divis - CEO & Director Susan Rodriguez - Chief Operating Officer Thomas S.
Neutral
GlobeNewsWire
2 weeks ago
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of Directors approved the grant of non-statutory options to eight (8) new employees to purchase 60,400 ordinary shares under Avadel's 2021 Inducement Plan. The awards were granted as an inducement material to the employee's acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of each new employee's respective start date and 25% vesting on the second, third, and fourth anniversary thereafter. The options are subject to the terms and conditions of Avadel's 2021 Inducement Plan approved by the Board of Directors in November 2021 and the terms and conditions of award agreements covering the grants.
Positive
The Motley Fool
2 weeks ago
Avadel (AVDL) Q2 Revenue Jumps 64%
Avadel (AVDL) Q2 Revenue Jumps 64%
Neutral
GlobeNewsWire
2 weeks ago
Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Guidance
-- Generated LUMRYZ™ net revenue of $68.1 million, a 64% increase compared to second quarter 2024, net income of $9.7 million and earnings per share of $0.10 -- -- 3,100 patients on LUMRYZ as of June 30, 2025, a 63% increase compared to June 30, 2024 -- -- Raises 2025 full year revenue guidance to $265 - $275 million -- -- Received Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the treatment of Idiopathic Hypersomnia (IH) -- -- On track to complete enrollment in pivotal Phase 3 REVITALYZ™ study evaluating efficacy and safety of LUMRYZ in IH by end of 2025 -- -- Avadel management to host conference call today at 8:30 a.m. ET -- DUBLIN, Ireland, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today increased its revenue guidance for the year as it announced its financial results for the second quarter ended June 30, 2025.
Neutral
GlobeNewsWire
3 weeks ago
Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2025 Financial Results on August 7
DUBLIN, Ireland, July 31, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, August 7, 2025, to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2025.
Neutral
GlobeNewsWire
1 month ago
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, July 21, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of Directors approved the grant of non-statutory options to six (6) new employees to purchase 34,200 ordinary shares under Avadel's 2021 Inducement Plan. The awards were granted as an inducement material to the employee's acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of each new employee's respective start date and 25% vesting on the second, third, and fourth anniversary thereafter. The options are subject to the terms and conditions of Avadel's 2021 Inducement Plan approved by the Board of Directors in November 2021 and the terms and conditions of award agreements covering the grants.
Neutral
Business Wire
1 month ago
ASL Strategic Value Fund Issues Open Letter to Avadel Shareholders
GREENWICH, Conn. & CHESTERFIELD, Mo.--(BUSINESS WIRE)--ASL Strategic Value Fund, LP (together with its affiliates, “ASL Strategic Value Fund” or “we”), a significant shareholder of Avadel Pharmaceuticals plc (NASDAQ: AVDL) (“Avadel” or the “Company”), today issued an open letter calling on Avadel's shareholders to vote AGAINST all of the Company's director nominees up for election at the 2025 annual general meeting of shareholders scheduled for July 29, 2025 (the “Annual Meeting”). The full tex.
Negative
Reuters
1 month ago
ASL pushes for board shakeup at Avadel over handling of sleep drug rollout
ASL Strategic Value Fund on Monday urged shareholders of Avadel Pharmaceuticals to replace its board, citing mismanagement in the rollout of the drugmaker's flagship sleep disorder drug Lumryz since its launch two years ago.
Neutral
GlobeNewsWire
1 month ago
Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act Litigation
DUBLIN, June 30, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that, on Friday, June 27, 2025, the U.S. Court of Appeals for the District of Columbia Circuit (the “Appeals Court”) affirmed a prior decision of the U.S. District Court for the District of Columbia (the “District Court”) in favor of the U.S. Food and Drug Administration (“FDA”) in a suit brought by Jazz Pharmaceuticals Inc. (“Jazz”) regarding the FDA's approval of LUMRYZTM, the first and only once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy.
Charts implemented using Lightweight Charts™